Bellevue Group Ag Summit Therapeutics Inc. Transaction History
Bellevue Group Ag
- $4.39 Billion
- Q2 2025
A detailed history of Bellevue Group Ag transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 41,738 shares of SMMT stock, worth $1.07 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
41,738
Previous 67,685
38.33%
Holding current value
$1.07 Million
Previous $1.31 Million
31.95%
% of portfolio
0.02%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
261Shares Held
90.7MCall Options Held
4.55MPut Options Held
3.34M-
Baker Bros. Advisors LP New York, NY33.7MShares$866 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$223 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$203 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$103 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$100 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.17B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...